Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA-irinotecan plus carboplatin versus irinotecan plus carboplatin in extensive-stage small cell lung cancer
ACTRN12611000520932Phase 2Recruiting
- Sponsor
- SouthernBiotech
- Start
- Feb 2011
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HyCAMP in small cell lung cancer (SCLC) (2 arms), sponsored by SouthernBiotech. Primary endpoints: Incidence of grade 3 and 4 toxicity and Tumor stem cell burden. Started Feb 2011; status: recruiting.
02
Drugs
HyCAMP
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ACTRN12611000520932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000520932.